Interferons/NNS
induce/VBP
normal/JJ
and/CC
aberrant/JJ
retinoic-acid/NN
receptors/NNS
type/NN
alpha/NN
in/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
cells/NNS
:/:
potentiation/NN
of/IN
the/DT
induction/NN
of/IN
retinoid-dependent/JJ
differentiation/NN
markers/NNS
./.

Treatment/NN
of/IN
the/DT
acute/JJ
promyelocytic/JJ
(/(
APL/NN
)/)
cell/NN
line/NN
NB4/NN
with/IN
interferon/NN
alpha/NN
(/(
IFN/NN
(/(
alpha/NN
)/)
)/)
,/,
as/RB
well/RB
as/IN
IFN/NN
(/(
beta/NN
)/)
and/CC
gamma/NN
,/,
results/VBZ
in/IN
an/DT
increased/VBN
expression/NN
of/IN
the/DT
transcripts/NNS
coding/VBG
for/IN
retinoic-acid/JJ
receptor/NN
type/NN
alpha/NN
(/(
RAR/NN
(/(
alpha/NN
)/)
)/)
and/CC
the/DT
leukemia-specific/JJ
retinoic/JJ
acid/NN
receptor/NN
PML-RAR/NN
./.
=====
Transcriptional/JJ
induction/NN
of/IN
the/DT
RAR/NN
(/(
alpha/NN
)/)
and/CC
PML-RAR/NN
mRNAs/NNS
is/VBZ
rapid/JJ
and/CC
it/PRP
is/VBZ
parallelled/VBN
by/IN
an/DT
increase/NN
in/IN
the/DT
corresponding/JJ
proteins/NNS
./.
=====
Up-regulation/NN
of/IN
RAR/NN
(/(
alpha/NN
)/)
and/CC
PML-RAR/NN
gene/NN
expression/NN
by/IN
IFN/NN
(/(
alpha/NN
)/)
is/VBZ
accompanied/VBN
by/IN
a/DT
strong/JJ
potentiation/NN
in/IN
the/DT
induction/NN
of/IN
2/CD
retinoid-dependent/JJ
granulocytic/JJ
markers/NNS
,/,
i.e./FW
,/,
granulocyte-colony-stimulating/JJ
factor/NN
receptor/NN
mRNA/NN
and/CC
leukocyte/NN
alkaline/NN
phosphatase/NN
./.
=====
However/RB
,/,
IFN/NN
(/(
alpha/NN
)/)
does/VBZ
not/RB
have/VB
any/DT
effects/NNS
on/IN
the/DT
retinoid-dependent/JJ
regulation/NN
of/IN
the/DT
myeloid/JJ
surface/NN
markers/NNS
CD11b/NN
and/CC
CD33/NN
./.
=====
The/DT
IFN-dependent/JJ
increase/NN
in/IN
RAR/NN
(/(
alpha/NN
)/)
levels/NNS
and/CC
the/DT
enhancing/JJ
effect/NN
of/IN
the/DT
cytokine/NN
on/IN
retinoid-dependent/JJ
granulocytic/JJ
markers/NNS
expression/NN
may/MD
be/VB
a/DT
characteristic/NN
of/IN
PML-RAR/NN
positive/JJ
cells/NNS
,/,
since/IN
the/DT
phenomena/NNS
are/VBP
not/RB
observed/VBN
in/IN
HL-60/NN
promyelocytes/NNS
./.
=====
Interferons/NNS
as/RB
well/RB
as/IN
retinoids/NNS
inhibit/VBP
the/DT
growth/NN
of/IN
NB4/NN
cells/NNS
,/,
although/IN
the/DT
2/CD
classes/NNS
of/IN
compounds/NNS
do/VBP
not/RB
significantly/RB
interact/VBP
in/IN
terms/NNS
of/IN
anti-proliferative/JJ
activity/NN
./.
=====
These/DT
results/NNS
suggest/VBP
the/DT
possible/JJ
use/NN
of/IN
combinations/NNS
between/IN
IFNs/NNS
and/CC
retinoic/JJ
acid/NN
in/IN
the/DT
cyto-differentiating/JJ
treatment/NN
of/IN
APL/NN
patients/NNS
./.